MedTrace Logo

A Study of Ruxolitinib for Preventing Graft-Versus-Host Disease in People With a Hematologic Malignancy Who Will Receive a Stem Cell Transplant

NCT07359859 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2026-02-17

No results posted yet for this study

Summary

The researchers are doing this study to compare 2 different GVHD prevention (prophylaxis) approaches. The researchers will see which approach is good or more effective at preventing chronic GVHD until 1 year after allogeneic hematopoietic stem cell transplantation (allo-HCT).

Conditions

Interventions

DRUG

Cyclophosphamide

An intermediate dose (medium dose) of Post-transplant Cyclophosphamide

DRUG

Cyclophosphamide

A full dose of Post-transplant Cyclophosphamide

DRUG

Mycophenolate Mofetil

Day +5 to +35

DRUG

Ruxolitinib

twice a day

DRUG

Tacrolimus

Day +5, taper per SoC

DRUG

Tacrolimus

Day +5, taper initiation within 2 weeks of starting Ruxolitinib

Sponsors & Collaborators

Principal Investigators

  • Doris Ponce, MD, MS · Memorial Sloan Kettering Cancer Center

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-01-20
Primary Completion
2029-01-31
Completion
2029-01-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07359859 on ClinicalTrials.gov